Ocuphire Pharma has announced the acquisition of Opus Genetics to create a biotech company dedicated to gene therapy ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted ...

Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, ...

Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late024.

Ocuphire Pharma (OCUP) announced the all-stock acquisition of Opus Genetics. In connection with the merger, the combined company will be ...

The company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stockholders of Opus Genetics. Ocuphire insiders ...

(RTTNews) - Ocuphire Pharma, Inc. (OCUP), Monday announced the results of two Phase 3 clinical trials of Phentolamine Ophthalmic Solution 0.75 percent, marketed as Ryzumvi, for the treatment of ...

FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing ...